Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Study to Evaluate the Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QoLESS AZA-AMLE)

Next Previous
Trial Profile

A Randomized Study to Evaluate the Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QoLESS AZA-AMLE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms QoLESS AZA-AMLE

Most Recent Events

  • 17 Jun 2021 Results of a comparative analysis of relative efficacy of maintenance therapy with oral versus injectable azacitidine in patients with Acute-myeloid-leukaemia in first remission after chemotherapy performed by matching individual patients data from QUAZAR AML-001 study to summary level data from the HOVON97 and QoLESS studies presented at the 26th Congress of the European Haematology Association
  • 08 Dec 2020 Results of QUAZAR AML-001 study of CC-486 versus PBO, and 2 studies of injectable AZA versus control (HOVON 97 and QoLESS) assessing an Indirect Treatment Comparison to evaluate the comparative efficacy of CC-486 versus injectable AZA as maintenance therapy in pts with AML in first remission after intensive chemotherapy, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
  • 10 Dec 2019 Status changed from recruiting to completed, according to results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top